Department of Epidemiology, Guangdong Provincial Key Laboratory of Tropical Disease Research, School of Public Health, Southern Medical University, Guangzhou, China.
Department of Public Health, Shenzhen Qianhai Shekou Free Trade Zone Hospital, Shenzhen, China.
Front Cell Infect Microbiol. 2023 Dec 18;13:1258550. doi: 10.3389/fcimb.2023.1258550. eCollection 2023.
Herd immunity against norovirus (NoV) is poorly understood in terms of its serological properties and vaccine designs. The precise neutralizing serological features of genotype I (GI) NoV have not been studied.
To expand insights on vaccine design and herd immunity of NoVs, seroprevalence and seroincidence of NoV genotypes GI.2, GI.3, and GI.9 were determined using blockade antibodies based on a 5-year longitudinal serosurveillance among 449 residents in Jidong community.
Correlation between human histo-blood group antigens (HBGAs) and GI NoV, and dynamic and persistency of antibodies were also analyzed. Seroprevalence of GI.2, GI.3, and GI.9 NoV were 15.1%-18.0%, 35.0%-38.8%, and 17.6%-22.0%; seroincidences were 10.0, 21.0, and 11.0 per 100.0 person-year from 2014 to 2018, respectively. Blockade antibodies positive to GI.2 and GI.3 NoV were significantly associated with HBGA phenotypes, including blood types A, B (excluding GI.3), and O; Lewis phenotypes Le/Le and Le/Le; and secretors. The overall decay rate of anti-GI.2 antibody was -5.9%/year (95% CI: -7.1% to -4.8%/year), which was significantly faster than that of GI.3 [-3.6%/year (95% CI: -4.6% to -2.6%/year)] and GI.9 strains [-4.0%/year (95% CI: -4.7% to -3.3%/year)]. The duration of anti-GI.2, GI.3, and GI.9 NoV antibodies estimated by generalized linear model (GLM) was approximately 2.3, 4.2, and 4.8 years, respectively.
In conclusion, enhanced community surveillance of GI NoV is needed, and even one-shot vaccine may provide coast-efficient health benefits against GI NoV infection.
针对诺如病毒（NoV）的群体免疫，其血清学特性和疫苗设计仍知之甚少。I 型（GI）NoV 的精确中和血清学特征尚未得到研究。
为了深入了解 NoV 的疫苗设计和群体免疫，我们使用基于阻断抗体的方法，对 449 名居住在冀东社区的居民进行了为期 5 年的纵向血清监测，以确定 GI.2、GI.3 和 GI.9 基因型的血清阳性率和血清发生率。
还分析了人类组织血型抗原（HBGAs）与 GI NoV 的相关性，以及抗体的动态和持久性。GI.2、GI.3 和 GI.9 NoV 的血清阳性率分别为 15.1%-18.0%、35.0%-38.8%和 17.6%-22.0%；2014 年至 2018 年，血清发生率分别为 10.0、21.0 和 11.0/100.0 人年。对 GI.2 和 GI.3 NoV 呈阻断抗体阳性的与 HBGA 表型显著相关，包括血型 A、B（不包括 GI.3）和 O；Lewis 表型 Le/Le 和 Le/Le；以及分泌者。抗 GI.2 抗体的总体衰减率为-5.9%/年（95%CI：-7.1%至-4.8%/年），明显快于 GI.3[-3.6%/年（95%CI：-4.6%至-2.6%/年)]和 GI.9 株[-4.0%/年（95%CI：-4.7%至-3.3%/年)]。广义线性模型（GLM）估计的抗 GI.2、GI.3 和 GI.9 NoV 抗体持续时间分别约为 2.3、4.2 和 4.8 年。
总之，需要加强对 GI NoV 的社区监测，即使是单次疫苗接种也可能提供针对 GI NoV 感染的具有成本效益的健康益处。
